PMEL Recombinant Rabbit mAb (一抗) - WB,IHC-P,IHC-F,IF | Bioss

bsm-61122R

重组兔单抗、mIHC精品抗体

PMEL Recombinant Rabbit mAb

黑色素瘤相关抗原gp100重组兔单抗

D12S53E; HMB-45; HMB45; ME20; ME20-M; ME20M; P1; P100; PMEL17; SI; SIL; SILV; gp100; D10H12S53E; D12S53Eh; gp87; PMEL_BOVIN; PMEL; Melanocyte protein Pmel 17; Premelanosome protein; Retinal pigment epithelial-specific protein; Silver locus protein homolog; RPE1; PMEL_HUMAN; ME20-M (ME20M); Melanocytes lineage-specific antigen GP100; Melanoma-associated ME20 antigen; PMEL_MOUSE; Silver locus protein; silver (mouse homolog) like; silver homolog (mouse)

Rabbit

A synthesized peptide derived from human PMEL: 600-661/661

IgG

Liquid

affinity purified by Protein A

Recombinant

11E7

70 kDa

100 kDa

10mM phosphate buffered saline(pH 7.4) with 150mM sodium chloride, 0.05% BSA, 0.02% Proclin300 and 50% glycerol.

Store at 4℃ for short term. Store at -20℃ for long term. Avoid repeated freeze/thaw cycles.

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

Plays a central role in the biogenesis of melanosomes. Involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distinct fibrillar structures. Release of the soluble form, ME20-S, could protect tumor cells from antibody mediated immunity.

PMEL

Melanocyte protein PMEL

Secreted and Endoplasmic reticulum membrane. Golgi apparatus. Melanosome. Endosome > multivesicular body. Identified by mass spectrometry in melanosome fractions from stage I to stage IV. Localizes predominantly to intralumenal vesicles (ILVs) within multivesicular bodies. Associates with ILVs found within the lumen of premelanosomes and melanosomes and particularly in compartments that serve as precursors to the striated stage II premelanosomes.Target information above from: UniProt accession P40967 The UniProt Consortium The Universal Protein Resource (UniProt) in 2010 Nucleic Acids Res. 38:D142-D148 (2010) .

Preferentially expressed in melanomas. Some expression was found in dysplastic nevi. Not found in normal tissues nor in carcinomas. Normally expressed at low levels in quiescent adult melanocytes but overexpressed by proliferating neonatal melanocytes and during tumor growth.

A small amount of P1/P100 (major form) undergoes glycosylation to yield P2/P120 (minor form). P2 is cleaved by a furin-like proprotein convertase (PC) in a pH-dependent manner in a post-Golgi, prelysosomal compartment into two disulfide-linked subunits: a large lumenal subunit, M-alpha/ME20-S, and an integral membrane subunit, M-beta. Despite cleavage, only a small fraction of M-alpha is secreted, whereas most M-alpha and M-beta remain associated with each other intracellularly. M-alpha is further processed to M-alpha N and M-alpha C. M-alpha C further undergoes processing to yield M-alpha C1 and M-alpha C3 (M-alpha C2 in the case of PMEL17-is or PMEL17-ls). Formation of intralumenal fibrils in the melanosomes requires the formation of M-alpha that becomes incorporated into the fibrils. Stage II melanosomes harbor only Golgi-modified Pmel17 fragments that are derived from M-alpha and that bear sialylated O-linked oligosaccharides.
N-glycosylated. O-glycosylated; contains sialic acid.

Belongs to the PMEL/NMB family.
Contains 1 PKD domain.

Plays a central role in the biogenesis of melanosomes. Involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distinct fibrillar structures. Release of the soluble form, ME20-S, could protect tumor cells from antibody mediated immunity.